A phase I trial of gamma-delta T cell immunotherapy candidate for the treatment of glioblastoma
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Allogeneic-gamma-delta-T-cell-therapy (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 16 Oct 2018 According to an Incysus Therapeutics media release, this trial expected to begin in early 2019.
- 07 May 2018 According to an Incysus Therapeutics media release, Incysus changed its name to Incysus Therapeutics.
- 20 Mar 2018 According to an Incysus media release, trial design will be presented at the 2018 CAR-T Congress USA Meeting.